Paul Eckburg, M.D. is an Infectious Diseases physician and Chief Medical Officer of Flightpath and has worked in clinical research and anti-infective drug development for over 26 years. Dr. Eckburg has served as CMO for Zavante Therapeutics, Geom Therapeutics, Utility Therapeutics, Bugworks Research, AN2 Therapeutics, and NovoBiotic, among others. He has been involved in the development of multiple approved anti-infective products, such as ceftaroline fosamil (Teflaro®), inhaled levofloxacin (QuinsairTM), ceftazidime-avibactam (Avycaz®), omadacycline (Nuzyra®), IV fosfomycin (Contepo®), and tebipenem (Utebzi®). Dr. Eckburg received his Bachelor of Science in Cell and Structural Biology from the University of Illinois at Urbana-Champaign and his M.D. from Rush University. He completed both Internal Medicine residency and Infectious Diseases fellowship at Stanford University School of Medicine, where he continues to teach as an Adjunct Clinical Assistant Professor.